Hope For Postpartum Depression: This Company To Launch Clinical Trial On Next-Gen Psychedelic
Portfolio Pulse from Lara Goldstein
Reunion Neuroscience has received FDA clearance to begin a Phase 2 study of RE104, a novel serotonergic psychedelic compound for treating postpartum depression (PPD). The company, which recently went private after listing on NASDAQ, will commence its multicenter, randomized, double-blind, placebo-controlled trial in Q4 2023. The trial will evaluate the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with PPD. RE104 is protected under U.S. patent No. 11,292,765, but there's an ongoing legal battle over the compound's creative ownership, including a lawsuit filed by Reunion against Mindset Pharma.

September 18, 2023 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mindset Pharma is involved in a legal battle with Reunion Neuroscience over the creative ownership of the compound RE104.
The ongoing legal battle over the ownership of the compound RE104 could potentially impact Mindset Pharma's operations and reputation, which could negatively affect its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50